Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aptabio Therapeutics NOX2 compound com-19
- Development stage
- Unknown
- Lead developer
- Aptabio Therapeutics
01
Overview
Aptabio Therapeutics NOX2 compound com-19: sourced facts only. name: "Based on these findings, we confirmed the effects of NOX2 inhibition using com-19, a selective NOX inhibiting molecule." [DOI:10.1158/1538-7445.am2025-2238]; target: "Based on these findings, we confirmed the effects of NOX2 inhibition using com-19, a selective NOX inhibiting molecule." [DOI:10.1158/1538-7445.am2025-2238]; developer: "Aptabio Therapeutics Inc., Yongin, Republic of Korea." [DOI:10.1158/1538-7445.am2025-2238]; stage: "Importantly, the results also demonstrated that com-19 inhibited pCAF-induced M2-like polarization of THP-1." [DOI:10.1158/1538-7445.am2025-2238]
02
Targets
NOX2 (NADPH oxidase 2)
Beyond the preview
Go deeper on Aptabio Therapeutics NOX2 compound com-19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aptabio Therapeutics NOX2 compound com-19.